Executive Interview: Leo's Gitte Aabo Talks New Products, Business Change
This article was originally published in Scrip
Denmark's dermatology-focused Leo Pharma has a new product for actinic keratosis in Phase III clinical studies and several investigational products in Phase II, potential new drugs that could continue a turnaround in business activity that just days ago included completion of the purchase of Astellas's dermatology portfolio, and over the past 12 months has seen top management reorganized and digital health and open innovation embraced.
You may also be interested in...
Executive Interview: Gitte Aabo On Leo Pharma's Innovation Strategy
The head of Denmark's multinational specialty dermatology company has unveiled a strategy to the year 2025 that includes a large increase in R&D spending, a continued interest in bulking up its established products business, and improving its commercial presence in Latin America and other markets.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.